# Deborah K. Armstrong

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/deborah-k-armstrong/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,546 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 73 |
| i10-index | 195 |
| OpenAlex ID | https://openalex.org/A5090143508 |
| ORCID iD | https://orcid.org/0000-0003-0852-803X |
| Works | 432 |

## Researcher papers

Showing 12 of 13.

- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer](https://scholariq.org/papers/intraperitoneal-cisplatin-and-paclitaxel-in-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/prognostic-factors-for-stage-iii-epithelial-ovarian-cancer-a-gynecologic/)
- [Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer](https://scholariq.org/papers/phase-ii-study-of-bevacizumab-in-patients-with-platinum-resistant-ovarian-cancer/)
- [Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-2-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of/)
- [NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022](https://scholariq.org/papers/nccn-guidelines-insights-ovarian-cancer-version-3-2022/)
- [Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-society-of-2/)
- [Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Toxin Mechanisms and Immunotoxins](https://scholariq.org/topics/toxin-mechanisms-and-immunotoxins-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.